Grimes & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.1M | Sell |
103,634
-6,186
| -6% | -$1.33M | 0.56% | 38 |
|
|
2026
Q1 | $23.9M | Buy |
109,820
+606
| +0.6% | +$134K | 0.66% | 27 |
|
|
2025
Q4 | $25M | Buy |
109,214
+2,228
| +2% | +$508K | 0.6% | 33 |
|
|
2025
Q3 | $24.8M | Buy |
106,986
+1,708
| +2% | +$348K | 0.61% | 31 |
|
|
2025
Q2 | $19.5M | Buy |
105,278
+2,172
| +2% | +$404K | 0.53% | 36 |
|
|
2025
Q1 | $21.6M | Buy |
103,106
+852
| +0.8% | +$166K | 0.67% | 30 |
|
|
2024
Q4 | $18.2M | Buy |
102,254
+645
| +0.6% | +$119K | 0.52% | 44 |
|
|
2024
Q3 | $20.1M | Buy |
101,609
+1,039
| +1% | +$194K | 0.54% | 38 |
|
|
2024
Q2 | $17.2M | Buy |
100,570
+329
| +0.3% | +$54.5K | 0.52% | 44 |
|
|
2024
Q1 | $18.3M | Buy |
100,241
+880
| +0.9% | +$152K | 0.56% | 45 |
|
|
2023
Q4 | $15.4M | Buy |
99,361
+4,251
| +4% | +$620K | 0.51% | 48 |
|
|
2023
Q3 | $14.2M | Sell |
95,110
-185
| -0.2% | -$27.2K | 0.55% | 41 |
|
|
2023
Q2 | $12.8M | Buy |
95,295
+688
| +0.7% | +$101K | 0.46% | 50 |
|
|
2023
Q1 | $15.1M | Buy |
94,607
+3,223
| +4% | +$493K | 0.62% | 36 |
|
|
2022
Q4 | $14.8M | Buy |
91,384
+3,096
| +4% | +$475K | 0.62% | 28 |
|
|
2022
Q3 | $11.8M | Buy |
88,288
+847
| +1% | +$122K | 0.62% | 35 |
|
|
2022
Q2 | $13.4M | Sell |
87,441
-409
| -0.5% | -$62.5K | 0.68% | 30 |
|
|
2022
Q1 | $14.2M | Buy |
87,850
+785
| +0.9% | +$114K | 0.74% | 38 |
|
|
2021
Q4 | $11.8M | Buy |
87,065
+811
| +0.9% | +$95.8K | 0.54% | 54 |
|
|
2021
Q3 | $9.3M | Buy |
86,254
+1,487
| +2% | +$170K | 0.4% | 66 |
|
|
2021
Q2 | $9.55M | Buy |
84,767
+1,736
| +2% | +$196K | 0.41% | 65 |
|
|
2021
Q1 | $8.99M | Buy |
83,031
+6,681
| +9% | +$715K | 0.43% | 65 |
|
|
2020
Q4 | $8.18M | Buy |
76,350
+1,761
| +2% | +$169K | 0.43% | 65 |
|
|
2020
Q3 | $6.53M | Buy |
74,589
+887
| +1% | +$83.5K | 0.42% | 69 |
|
|
2020
Q2 | $7.24M | Buy |
73,702
+656
| +0.9% | +$57.8K | 0.5% | 62 |
|
|
2020
Q1 | $5.57M | Buy |
73,046
+27,396
| +60% | +$2.33M | 0.51% | 50 |
|
|
2019
Q4 | $4.04M | Buy |
45,650
+495
| +1% | +$41.1K | 0.26% | 78 |
|
|
2019
Q3 | $3.42M | Buy |
45,155
+833
| +2% | +$57.1K | 0.24% | 76 |
|
|
2019
Q2 | $3.22M | Buy |
44,322
+107
| +0.2% | +$8.41K | 0.24% | 82 |
|
|
2019
Q1 | $3.56M | Sell |
44,215
-58
| -0.1% | -$4.75K | 0.28% | 80 |
|
|
2018
Q4 | $4.08M | Sell |
44,273
-1,008
| -2% | -$88.6K | 0.4% | 64 |
|
|
2018
Q3 | $4.28M | Sell |
45,281
-16
| -0% | -$1.52K | 0.34% | 70 |
|
|
2018
Q2 | $4.2M | Sell |
45,297
-112
| -0.2% | -$10.9K | 0.37% | 75 |
|
|
2018
Q1 | $4.3M | Buy |
45,409
+13,546
| +43% | +$1.49M | 0.42% | 66 |
|
|
2017
Q4 | $3.08M | Buy |
31,863
+27,567
| +642% | +$2.6M | 0.3% | 77 |
|
|
2017
Q3 | $382K | Buy |
4,296
+104
| +2% | +$7.92K | 0.04% | 153 |
|
|
2017
Q2 | $304K | Sell |
4,192
-51
| -1% | -$3.43K | 0.03% | 163 |
|
|
2017
Q1 | $276K | Buy |
4,243
+203
| +5% | +$12.8K | 0.03% | 171 |
|
|
2016
Q4 | $253K | Buy |
4,040
+177
| +5% | +$10.8K | 0.03% | 177 |
|
|
2016
Q3 | $244K | Buy |
+3,863
| New | +$250K | 0.03% | 171 |
|
|
2016
Q2 | – | Sell |
-3,700
| Closed | -$211K | – | 210 |
|
|
2016
Q1 | $211K | Buy |
3,700
+179
| +5% | +$9.98K | 0.03% | 181 |
|
|
2015
Q4 | $209K | Sell |
3,521
-370
| -10% | -$21.3K | 0.03% | 183 |
|
|
2015
Q3 | $212K | Sell |
3,891
-55
| -1% | -$3.58K | 0.03% | 172 |
|
|
2015
Q2 | $265K | Buy |
3,946
+200
| +5% | +$13.1K | 0.04% | 154 |
|
|
2015
Q1 | $219K | Buy |
3,746
+340
| +10% | +$20.5K | 0.05% | 145 |
|
|
2014
Q4 | $223K | Buy |
+3,406
| New | +$215K | 0.06% | 140 |
|
|
2014
Q3 | – | Sell |
-3,862
| Closed | -$218K | – | 166 |
|
|
2014
Q2 | $218K | Buy |
+3,862
| New | +$203K | 0.06% | 144 |
|
Other funds holding ABBV
Grimes & Company's ABBV Position: Q2 2026 in Review
Grimes & Company reduced its AbbVie (ABBV) stake by 5.6% in Q2 2026, selling an estimated $1.33M and leaving 103,634 shares worth $26.1M. The position accounts for 0.56% of the portfolio, ranked #38.
Grimes & Company first reported a position in ABBV in Q2 2014 and has held it in 47 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Grimes & Company held 103,634 shares of AbbVie worth $26.1M as of Q2 2026.
- Grimes & Company sold 6,186 AbbVie shares in Q2 2026, an estimated $1.33M.
- AbbVie made up 0.56% of Grimes & Company's portfolio in Q2 2026, its #38 holding.
- Grimes & Company first reported a position in AbbVie in Q2 2014 and has held it in 47 quarters since.
- 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.